Cytokinetics (NASDAQ:CYTK) and Tevogen Bio (NASDAQ:TVGN) Head-To-Head Analysis

Cytokinetics (NASDAQ:CYTK) and Tevogen Bio (NASDAQ:TVGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Valuation and Earnings

This table compares Cytokinetics and Tevogen Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	108.70	-$784.96 million	($6.84)	-11.24
Tevogen Bio	N/A	N/A	-$26.27 million	($9.50)	-0.79

Tevogen Bio has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Cytokinetics and Tevogen Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	3	17	1	2.82
Tevogen Bio	1	1	0	0	1.50

Cytokinetics currently has a consensus target price of $97.25, suggesting a potential upside of 26.45%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,236.90%. Given Tevogen Bio’s higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Cytokinetics.

Profitability

This table compares Cytokinetics and Tevogen Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Tevogen Bio	N/A	N/A	-610.37%

Summary

Cytokinetics beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.